- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02520466
Cocoa Flavanol and Coronary Vasomotion Vascular Function in Patients With Coronary Artery Disease
Effect of Cocoa Flavanol-containing Drink on Coronary Vascular Function in Patients With Coronary Artery Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland
- Cardiovascular Center Cardiology Univeristy Hospital of Zurich
-
Zurich, Switzerland
- Universisty Hospital of Zurich, Cardiovascular Center Cardiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with coronary artery disease undergoing elective coronary angiography with or without the need of coronary intervention
- Age 20 - 80
- Written obtained informed consent
Exclusion Criteria:
- Acute ST-elevation myocardial infarction
- Acute non-ST-elevation myocardial infarction (enzyme positive)
- Ventricular tachy-arrythmias or AV-Block >I°
- Renal insufficiency (GFR MDRD < 30ml/min) or liver disease (ALT or AST >150 IU)
- Pregnancy
- Known allergy to compounds of cocoa product
- Known allergy to contrast media
- Known allergy to nuts
- Intolerance to coffein and theobromin
- Acute infectious disease
- Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)
- Participation in another study within the last month
- Concomitant vitamin supplements and herbal remedies, as well as fruit and tea extracts
- No study visits ± 1 week before Eastern, Christmas and New Year holyday (altered eating habits)
- Extreme eating habits (as assessed by a questionnaire)
- Alcohol or drug abuse
- Lactose intolerance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: flavanol-containing drink
|
Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
|
Placebo Comparator: flavanol-free drink
flavanol-free drink matched for taste and calories
|
Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
coronary endothelial function as assessed as response to cold pressor test
Time Frame: 2 hours
|
Primary endpoint will be the improvement in coronary endothelial function in response to cold pressor testing (i.e. % reduction in coronary artery constriction compared to baseline) 2h after ingestion of a cocoa flavanol rich-drink or placebo drink, respectively. In a subset of patients daily consumption of a flavanol-drink will be assessed and outcomes measured after 3-4 weeks. |
2 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas F Lüscher, Prof MD, University Hospital Zurich, Cardiovascular Center Cardiology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EK2012-0201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stable Coronary Heart Disease
-
Herlev and Gentofte HospitalUnknownCoronary Heart Disease | Ischemic Heart Disease | Stable AnginaDenmark
-
Guang'anmen Hospital of China Academy of Chinese...UnknownCoronary Heart Disease | Stable Angina
-
Guang'anmen Hospital of China Academy of Chinese...UnknownCoronary Heart Disease | Stable Angina
-
Merck KGaA, Darmstadt, GermanyMerck Serono Co., Ltd., ChinaCompletedCoronary Disease | Stable AnginaChina
-
University of EdinburghImperial College LondonTerminatedAngina Pectoris | Coronary Heart DiseaseUnited Kingdom
-
Yonsei UniversityRecruitingMyocardial Ischemia(Implanted Drug-eluting Stents Because of Ischemic Heart Disease(Stable Angina, Acute Coronary Syndrome))Korea, Republic of
-
CGBio Inc.UnknownIschemic Heart Disease | Stable Angina | Unstable Angina | NSTEMI - Non-ST Segment Elevation MI | Stable Coronary Artery DiseaseKorea, Republic of
-
MedImmune LLCCompletedStable Coronary Heart DiseaseUnited States
-
Ajou University School of MedicineB. Braun Korea Co., Ltd.UnknownStable Angina, Unstable Angina, Silent Coronary Ischemia, Coronary Artery DiseaseKorea, Republic of
-
AstraZenecaCompleted
Clinical Trials on flavanol-rich drink vs flavanol-free drink
-
University of California, DavisMars, Inc.Completed
-
Heinrich-Heine University, DuesseldorfUniversity of ReadingCompleted
-
Heinrich-Heine University, DuesseldorfCompleted
-
Laval UniversityCompleted
-
University of ReadingCompleted
-
University of California, DavisCompleted
-
Lund UniversityAnti-Diabetic Food CentreCompletedMood | Cognitive Performance | Cardiometabolic Risk MarkersSweden
-
Laval UniversityCompleted
-
University of ReadingUnknown
-
University of OuluSeinajoki Central HospitalCompleted